Eli Lilly is in advanced talks to acquire Ventyx Biosciences for more than $1 billion.[1][2][3] Ventyx Biosciences is developing drugs in tablet form for autoimmune diseases such as Crohn's disease, ulcerative colitis, and rheumatoid arthritis.[1][2] The acquisition would expand Eli Lilly's inflammatory bowel disease portfolio and add experimental drugs for Parkinson's disease, obesity-related cardiovascular disease and other conditions.[1][2] Shares of Ventyx Biosciences rose 5.2% after the news and trading was temporarily suspended due to volatility.[1][3] Before the report, Ventyx had a market capitalization of around $500 million, which the acquisition would double.[2][3] A deal could be announced soon, according to sources cited by the Wall Street Journal.[1][2][3]